This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

NitroMed Fires Sales Reps

Beleaguered drugmaker NitroMed (NTMD) has changed its marketing strategy again as it tries to stimulate sales for BiDil, the congestive heart failure medication for African-Americans.

NitroMed, of Lexington, Mass., said Wednesday that it will fire its 120-member salesforce and replace it with a small group of marketing specialists to target experts in heart disease. BiDil reached the market in July 2005 and is the first medication approved for a specific ethnic group .

The decision represents an about-face by NitroMed, which originally hired 190 marketers on a contract basis to sell the heart drug to a wide range of physicians. When that strategy proved expensive and ineffective , NitroMed hired an in-house salesforce.

Now this tactic has failed, too, prompting investors to knock down NitroMed's stock by 20 cents, or 7.9%, to $2.33. The stock fell as far as $2.16, a 52-week low. NitroMed's stock has lost about 90% of its value since January 2005.

"Sales of BiDil have grown steadily, but they are not growing at a rate that supports the present sales structure," said Jerry Karabelas, chairman and CEO of NitroMed.

The drug has been hampered not only by past salesforce problems but also by the reluctance of health maintenance organizations and insurers to cover it at favorable rates. NitroMed initially had trouble convincing insurers to reduce the out-of-pocket expenses paid by consumers.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $128.90 -0.36%
FB $80.22 0.78%
GOOG $573.00 -0.11%
TSLA $199.00 -0.28%
YHOO $43.19 1.30%


DOW 18,093.66 -109.71 -0.60%
S&P 500 2,097.66 -10.12 -0.48%
NASDAQ 4,965.7940 -14.1070 -0.28%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs